Molecular assays for surveillance of antifolate-resistant malaria

Lancet

Volumn 351, Issue 9116, 1998, Pages 1629-1630

  Kublin, James G ^b   Witzig, Richard S ^b   Shankar, Anuraj H ^b   Zurita, Jorge Quintana ^b   Gilman, Robert H ^b   Guarda, Javier Aramburú ^b   Cortese, Joseph F ^b   Plowe, Christopher V ^a,b,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Department of Public Health ^*

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID ANTAGONIST;

MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0032580723     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)24022-0     Document Type: Article

References (5)

1. 1 Peters W. Chemotherapy and drug resistance in malaria. London: Academic Press, 1987.
2. 2 Peterson DSA, Milhous WK, Wellems TE. Molecular basis of differential resistance to cycloguanil and pyrimethamine in plasmodium falciparum malaria. Proc Natl Acad Sci USA 1990; 87: 3018-22.
3. 3 Wang P, Read M, Sims PF, Hyde JE. Sulfadoxine resistance in the human parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Molec Microbiol 1997; 23: 979-86.
4. 4 Plowe CV, Djimde A, Wellems TE, Kouriba B, Doumbo OK. Community pyrimethamine use and prevalence of resistant Plasmodium falciparum genotypes in Mali: a model for deterring resistance. Am J Trop Med Hyg 1996; 55: 467-71.
5. 5 Plowe CV, Cortese JF, Djimde A, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997; 176: 1590-96.